Anteris Technologies Global Corp. AVR R2K
Company Overview
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -11.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -31.5%, profit CAGR -84.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -31.51% |
| 1 Year: | -11.20% |
Compounded Profit Growth
| 5 Years: | -84.01% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +191.53% |
| 6 Months: | +96.70% |
| 3 Months: | +44.35% |
| 1 Month: | -3.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)43.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -31.5% CAGR over 5 years.
- Earnings shrank at -84.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVR Anteris Technologies Global Corp. R2K | 8.95 | -4.03 | $871.21M | 0.00% | - | -59.21% | -31.51% | -84.01% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 766.00K | 632.00K | 768.98K | - | - | - | - |
| Cost of Revenue | - | - | 443.55K | - | - | - | - |
| Gross Profit | - | - | 325.44K | - | - | - | - |
| Operating Expenses | - | - | 20.92M | - | - | - | - |
| Operating Income | -17.79M | -18.47M | -20.60M | - | - | - | - |
| EBITDA | - | - | -21.40M | - | - | - | - |
| Interest Expense | - | - | 11.74K | - | - | - | - |
| Pretax Income | - | - | -21.79M | - | - | - | - |
| Tax Provision | - | - | 0 | - | - | - | - |
| Net Income | -16.35M | -18.71M | -21.86M | - | - | - | - |
| Diluted EPS | -0.91 | -0.98 | -1.07 | -0.61 | -0.58 | -0.62 | -0.28 |
| R&D Expense | 11.56M | 12.63M | 13.95M | 16.46M | 16.34M | 16.81M | 17.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.83M | 3.20M | 2.73M | - | - |
| Cost of Revenue | 3.93M | 2.90M | 1.86M | - | - |
| Gross Profit | 1.91M | 298.38K | 876.80K | - | - |
| Operating Expenses | 18.23M | 31.79M | 47.53M | - | - |
| Operating Income | -16.32M | -31.49M | -46.66M | - | - |
| EBITDA | -15.50M | -29.14M | -45.54M | - | - |
| Interest Expense | 1.03M | 648.71K | 67.09K | - | - |
| Pretax Income | -17.17M | -30.56M | -46.76M | - | - |
| Tax Provision | 0 | 0 | 0 | - | - |
| Net Income | -17.17M | -30.56M | -46.02M | - | - |
| Diluted EPS | - | -2.26 | -2.94 | -3.77 | -2.55 |
| R&D Expense | - | - | - | 51.45M | 69.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | 21.43M | 15.99M | 30.53M | 80.70M | 23.00M |
| Current Assets | 18.75M | 12.24M | 24.22M | - | - |
| Cash & Equivalents | 15.46M | 9.29M | 21.03M | - | - |
| Inventory | 549.82K | 355.62K | 442.35K | - | - |
| Receivables | 204.99K | 440.93K | 407.56K | - | - |
| Total Liabilities | 10.91M | 6.95M | 11.63M | 18.02M | 23.25M |
| Current Liabilities | 10.20M | 6.05M | 9.46M | 16.56M | 21.37M |
| Long Term Debt | - | - | 93.84K | - | - |
| Total Debt | 4.14M | 952.79K | 1.69M | - | - |
| Total Equity | 10.52M | 9.03M | 19.30M | 62.76M | -93.00K |
| Shares Outstanding | 35.94M | 35.94M | 35.94M | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -14.44M | -29.42M | -34.63M | -61.24M | -77.80M |
| Investing Cash Flow | -886.07K | -992.57K | -2.58M | -2.28M | -596.00K |
| Financing Cash Flow | 27.42M | 23.27M | 49.34M | 112.83M | 20.55M |
| Capital Expenditure | -582.24K | -1.67M | -2.39M | -2.27M | -1.95M |
| Free Cash Flow | -15.02M | -31.08M | -37.03M | -63.51M | -79.76M |
| Net Change in Cash | 12.09M | -7.14M | 12.13M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | 32.7% | 9.3% | 32.1% | - | - |
| Operating Margin % | -279.9% | -983.8% | -1,706.0% | - | - |
| Net Margin % | -294.5% | -954.9% | -1,682.8% | - | - |
| ROE % | -163.1% | -338.3% | -238.4% | - | - |
| ROCE % | -145.2% | -316.8% | -221.4% | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | L1 Capital Pty Ltd | 8.00% | 7.79M | $79.53M |
| 2 | Nantahala Capital Management, LLC | 5.68% | 5.53M | $56.47M |
| 3 | Sio Capital Management, LLC | 5.53% | 5.38M | $54.96M |
| 4 | Blackrock Inc. | 5.02% | 4.89M | $49.92M |
| 5 | Adar1 Capital Management, LLC | 3.89% | 3.79M | $38.69M |
| 6 | Perceptive Advisors Llc | 3.52% | 3.43M | $34.97M |
| 7 | RA Capital Management, L.P. | 3.08% | 3.00M | $30.63M |
| 8 | BVF Inc. | 3.08% | 3.00M | $30.63M |
| 9 | FMR, LLC | 2.98% | 2.90M | $29.62M |
| 10 | Ensign Peak Advisors, Inc | 2.14% | 2.09M | $21.31M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVR
TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge
For more than two decades, transcatheter aortic valve replacement (TAVR) has been celebrated as one of cardiovascular medicine's great procedural success stories. It made valve replacement possible for patients once considered too high-risk…
France clearance marks key milestone for Anteris' pivotal PARADIGM Trial
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full regulatory clearance from France's National Agency for Medicines and Health Products Safety (ANSM) for its global pivotal PARADIGM Trial, paving the way for patient recruit…
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the French Nat…
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercia…
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan Knight and company veteran Stephen Denaro as directors. Knight joins as a Class I dire…
AVR — Frequently Asked Questions
What is the current share price of Anteris Technologies Global Corp. (AVR)?
As of 2026-07-14 21:23 PDT, Anteris Technologies Global Corp. (AVR) trades at $8.95 on NasdaqGM. Its 52-week range is $2.90 to $10.57.
What is the market capitalisation of AVR?
Anteris Technologies Global Corp. (AVR) has a market capitalisation of $871.21M on NasdaqGM.
What is the P/E ratio of AVR?
AVR trades at a trailing price-to-earnings (P/E) ratio of -4.03. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.19.
What is the return on equity (ROE) of AVR?
AVR has a return on equity (ROE) of -59.21%.
Is AVR a good stock to buy?
This page provides a data-driven analysis of Anteris Technologies Global Corp. (AVR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.